| Name | Title | Contact Details |
|---|
Gradientech is developing the microfluidic platform of tomorrow, today. Our revolutionising in vitro diagnostic system, QuickMIC®, is designed to strengthen labs by providing reliable results, at outstanding speed. Visit to experience how.
Sage Bionetworks is a nonprofit biomedical research and technology development organization that was founded in Seattle in 2009. We develop and apply open practices to data-intensive research for the advancement of human health. Data-intensive research has become an important component of biomedicine, but it`s not always easy to understand how to apply computational approaches appropriately or how to interpret their results. Sage believes open practices can help. Our interdisciplinary team of scientists and engineers work together to provide researchers access to technology tools and scientific approaches to share data, benchmark methods, and explore collective insights, all backed by Sage`s gold-standard governance protocols and commitment to user-centered design. Sage is supported through a portfolio of competitive research grants, commercial partnerships, and philanthropic contributions. Sage embraces diversity, equity and inclusion. We are committed to pay parity and making our salary ranges available to all employees. We invite you to apply and we welcome a conversation. We are based in Seattle, WA, and collaborate broadly throughout the world.
Advanced Life Sciences is a Woodridge, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HealthTell is committed to empowering the next generation of diagnostics and therapeutics for complex immune-mediated diseases such as cancer, autoimmune disorders, and infectious diseases. Based on robust proprietary technology, HealthTell is developing the first and only diagnostic platform capable of assessing an individual`s immune system response to specific diseases. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage health and make more informed decisions.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.